lymphoma

Altogether, 16 consecutive patients with MF/SS (MF 10, SS 6) received an alloHCT after TBI/fludarabine-based conditioning as institutional treatment standard between April 2014 and February 2025. Median age at transplantation …

A 21-year-old patient with aggressive lymphoma sought care at Cleveland Clinic Cancer Institute after rapid acceleration of her disease. Caring for a young patient with lymphoma and swift progression to …

NatureReal-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphomaPrior to the advent of chimeric antigen receptor (CAR) T-cell therapy, patients with relapsed/refractory (R/R) mantle cell …

Ferreri ITI, Calimeri T, Cwynarski K, Dietrich J, Grommas C, Hoang-Xuan K, et al. Central nervous system lymmoma. Nat Rev Distrim Prim. 2023;9:29. Article  PubMed  Google Scholar Ferreri AJ, Cwynarski …

Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre …

Competing interests HT received honoraria from AstraZeneca plc, Bristol Myers Squibb, Chugai Pharma, Janssen, Kyowa Kirin, Meiji Seika Pharma, Nippon Shinyaku, Mundipharma, Ono Pharmaceutical, SymBio pharmaceuticals, Takeda Pharmaceutical, Eisai, Fujimoto …

Characterization and injection of Car-T cells The median lentiviral CAR gene migration efficiency was 56.8% (range, 6.2-78.1%) for all CAR-T cells manufactured. All patients were administered fludarabine and cyclophosphamide (FC) …

Kessinger A, Armitage JO, Landmark J, Weisenburger D. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol. 1986;14:192–6. CAS  PubMed  Google Scholar  Kessinger A, Armitage JO, …

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: …